04

Patients

Serving patients with

commitment and humanity

For questions or interest in participating in our clinical trials, please email us.

Current Clinical Trials

RLY-2608 in PI3Kα-mutated Solid Tumors and Advanced Breast Cancer

First-in-Human ReDiscover-1 Trial (NCT05216432)
In a global first-in-human study, we are currently evaluating the pan mutant-selective PI3Kα inhibitor, RLY-2608, as a single agent in advanced solid tumor patients and in combination with fulvestrant in patients with HR+, HER2-, PI3Kα mutated advanced breast cancer.

RLY-2608 in PIK3CA-mutated Vascular Malformations

Phase 1/2 RLY-2608-201 Trial (NCT06789913)
In a global Phase 1/2 study, we are currently evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, RLY-2608, in adults and children with PIK3CA Related Overgrowth Spectrum (PROS) and malformations driven by PIK3CA mutation. PROS includes syndromes such as Klippel-Trenaunay syndrome, CLOVES syndrome, FAVA, and more. Other malformations include PIK3CA-driven lymphatic and venous malformations.

Expanded Access Policy

Relay Therapeutics is hyper-focused on bringing life-changing medicines to patients. Our goal is to provide access to our investigational therapies when it is appropriate. Read on to learn more.

We are constantly working with patients, their families, caregivers, and advocacy groups to learn about the challenges patients experience in their daily lives and how we can best support them from a therapeutic perspective and beyond.